67 results about "Muscle loss" patented technology

The invention relates to application of a yeast peptide-derived polypeptide in promoting proliferation and differentiation of myoblasts and a composition, and belongs to the technical field of biological medicines and nutrition and health care. The amino acid sequence of the polypeptide comprises SEQ ID No.1 (LGGPLL), SEQ ID No.2 (PQAVTI), SEQ ID No.3 (VASGGL) or SEQ ID No.4 (LGPTGISM, and the polypeptide can be used for remarkably promoting the proliferation and the cell cycle progress of C2C12 myoblasts and up-regulating the expression level of myogenic protein. The polypeptide can be used as an active component to be applied to development of anti-sarcopenia related medicines or functional food compositions. Cell experiments prove that the polypeptide has a good muscle promoting function and is suitable for intervention of senile muscle loss such as sarcopenia and the like.

Methods for treating muscle loss and exercise capacity pathologies by controlling osteocalcin release, and compositions therefor, are provided.

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

The present invention relates to a use of Cyclo-His Pro (CHP) alone or zinc and Cyclo-His Pro (zinc and CHP, Cycloz) for inhibiting muscle loss or alleviating muscle function decline caused by anti-obesity drugs. More specifically, the present invention provides a pharmaceutical composition and a health functional food composition, which when administered in combination with an anti-obesity drug, exhibit an effect of inhibiting the anti-obesity drug-induced side effect of muscle loss while maintaining a weight loss effect, and exhibit an effect of preventing, alleviating, or treating sarcopenic obesity, and a method for inhibiting muscle loss or alleviating muscle function decline caused by an anti-obesity drug and a method for preventing, alleviating or treating sarcopenic obesity using same.

The present invention relates to novel use of a cathepsin L inhibitor Z-Phe-Tyr-CHO (C26H26N2O5), wherein the cathepsin L inhibitor Z-Phe-Tyr-CHO inhibits cancer progression and cachexia and muscle damage that are caused by cancer, and thus can be effectively used for preventing, ameliorating or treating cachexia and muscle loss, while having anticancer activity.

The invention discloses a leg rehabilitation training device, and particularly relates to the technical field of medical instruments.The leg rehabilitation training device comprises a supporting assembly, a fixing assembly is installed on the upper portion of the supporting assembly, a cavity is formed in the right portion of the fixing assembly, an adjusting assembly is installed in the cavity, and a driving assembly is installed in an inner cavity of the fixing assembly; a training assembly is installed in an inner cavity of the fixing assembly. According to the leg rehabilitation training device, a patient does not need to get out of the bed by himself or herself through the designed adjusting assembly, the patient can be gradually transited from a lying state to a standing state by adjusting the stable angle of the turnover bed, and the safety risks such as falling and collision caused by lower limb weakness and lack of balance feeling in the whole process are avoided; meanwhile, by simulating the standing state, leg muscles can naturally bear the body weight, core muscle groups such as quadriceps femoris muscles and gastrocnemius muscles can be activated, muscle loss atrophy caused by long-term bed lying can be prevented, bone metabolism can be stimulated through load bearing, and the occurrence risk of osteoporosis can be reduced.

The invention discloses lactobacillus delbrueckii with a muscle protection function in a fat reducing period as well as a product and application thereof, belongs to the technical field of microorganisms, and discloses lactobacillus delbrueckii subsp. Lactis Turb8 with the preservation number of CGMCC No.35627. The lactobacillus delbrueckii subsp. Lactis Turb8 has the advantages that the preservation number is CGMCC No.35627; the strain or the preparation thereof can effectively prevent or improve the accompanying problems of muscle loss and function decline in the process of applying fat-reducing drugs such as GLP-1 receptor agonists (such as liraglutide and semeglutide), and the effect of reducing fat but not reducing muscle is achieved. The strain disclosed by the invention can be used for remarkably increasing the lean body mass ratio of a user, increasing the muscle mass of lower limbs, increasing the cross sectional area of muscle fibers and improving muscle function indexes such as strength of four limbs and suspension endurance while keeping the original weight-reducing effect of a fat-reducing medicine. The invention also relates to microbial agents comprising this strain, various preparations, their use in the preparation of products for ameliorating (in particular drug-induced) muscle reduction.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving senescence of a skeletal muscle system and application of the pharmaceutical composition. The pharmaceutical composition is composed of nicotinamide mononucleotide and apigenin. The composition has the advantages of being high in safety and easy to obtain, can synergistically promote cartilage, bone and muscle cell differentiation, delay cartilage degeneration and relieve bone and muscle loss, and has a good effect and application potential in the aspect of treating skeleton and muscle aging.

The present invention relates to a composition for strengthening muscle strength or preventing, ameliorating or treating muscle loss, comprising a Lilium lancifolium extract as an active ingredient. Specifically, when C2C12 cells were pre-treated with a Lilium lancifolium extract, and then treated with H2O2, dexamethasone, or TNF-α, muscle damage was alleviated and muscle loss was inhibited, and the muscle mass and grip strength decreased by dexamethasone administration in a muscle atrophy mouse model were increased upon administration of the Lilium lancifolium extract. Therefore, the composition can be effectively used as a health functional food, medicine or feed additive for strengthening muscle strength or preventing, ameliorating or treating muscle loss.

The present invention provides a therapeutic drug for frailty or muscular dystrophy, and particularly for sarcopenia, and a medicinal drug for improving motor function. The present invention provides a motor function improver that contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof and additionally contains an ATP precursor substance or is used in combination with an ATP precursor substance. The ATP precursor substance is preferably inosine, inosinic acid, or hypoxanthine. This motor function improver is preferably used as a medicinal drug and is used as a therapy or preventive for frailty and sarcopenia and as a therapy or preventive for muscle wasting and muscle loss.

This invention discloses a *Lactococcus faecium* strain, YS-IM01. This strain can efficiently hydrolyze sheep colostrum proteins and specifically release a large amount of leucine. This invention also provides a polypeptide composition comprising multiple active peptides with potential for muscle synthesis, immunomodulation, and antioxidant activity. This invention further provides a fermented sheep colostrum product obtained by fermenting sheep colostrum with the aforementioned *Lactococcus faecium*. This invention also provides a method for preparing the fermented sheep colostrum product, comprising steps including fermentation, low-temperature vacuum concentration, and vacuum freeze-drying. Simultaneously, this invention also provides a method for preparing a drug using *Lactococcus faecium* and the polypeptide composition to prevent and / or improve age-related muscle loss.

Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, for example, large volume muscle loss, including skeletal and heart muscle, blast wave injury, muscle loss from diabetes and resulting from frailty as a result of aging.

Provided is a pharmaceutical composition for preventing and treating muscle loss, containing Rhododendron mucronulatum extract as an active ingredient.

The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.

Methods of treating muscle atrophy (e.g., reduced muscle mass or muscle loss) using GSK-3β inhibitors are provided.

The present invention relates to a peptide having obesity and muscle loss inhibitory activities, and a use thereof. The peptide has excellent effects on suppressing appetite, promoting energy metabolism, inhibiting fat accumulation, and promoting lipolysis, and inhibits muscle atrophy while promoting muscle synthesis, such that the peptide can be effectively used for the prevention or treatment of obesity and sarcopenia.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

The present invention relates to a peptide having muscle formation-promoting activity, anti-obesity activity, fatty liver-inhibiting activity, or anti-diabetic activity, and to a use thereof. Specifically, the peptide of the present invention exhibits activities of inhibiting muscle loss, increasing muscle mass, promoting lipid degradation in hepatocytes or adipocytes, suppressing insulin resistance signaling, or enhancing insulin sensitivity signaling. The peptide of the present invention can be effectively used as an active ingredient in a pharmaceutical composition or a food composition for treating, preventing, or alleviating muscle diseases, obesity, fatty liver, or diabetes.

The present invention relates to a use of a precursor miRNA for preventing, alleviating, or treating muscle loss or muscle atrophy and, more specifically, to a composition for preventing, alleviating, or treating diseases caused by muscle loss or muscle atrophy, the composition comprising the precursor miRNA or an expression regulator thereof. The precursor miRNA according to the present invention was experimentally confirmed to exhibit a specific expression pattern in individuals with muscle loss or muscle atrophy compared to a normal control group. This indicates that the precursor miRNA according to the present invention and the expression regulator thereof have the effect of preventing, alleviating, or treating muscle loss or muscle atrophy, and thus the precursor miRNA according to the present invention can be widely used in the field of treating muscle loss or muscle atrophy.

The present invention relates to probiotic compositions comprising at least one Lactobacillus helveticus, at least one Bifidobacterium longum, and at least one Bifidobacterium animalis. The present invention further relates to methods of using said compositions for preventing muscle loss, improving or maintaining muscle strength, and maintaining intestinal barrier integrity.

The invention discloses a muscle-building dietary flavone compound protein composition as well as a preparation method and application thereof, and belongs to the field of dietary supplements. The composition is prepared from the following components in parts by weight: 50 to 80 parts of concentrated whey protein powder, 5 to 20 parts of separated whey protein powder, 0.01 to 3 parts of hydrolyzed whey protein powder, 0.1 to 1 part of bovine colostrum powder, 0.01 to 0.05 part of kaempferol and 0.01 to 0.1 part of glucomannan. The composition can improve the muscle synthesis and growth rate, inhibit muscle reduction caused by sarcopenia, improve the muscle oxidation resistance, accelerate the muscle repair speed and activate the protein synthesis rate-limiting enzyme AKT and the growth kinase ERK. The composition can be used for preparing food, special diet and health food.

The present invention relates to a phytochemical-containing albumin nanocomplex and a composition containing the same for improving muscle diseases. More specifically, the present invention relates to a phytochemical-containing albumin nanocomplex that has the effect of suppressing muscle loss caused by oxidative stress or inflammatory responses and promoting the differentiation of myoblasts into muscle cells. The phytochemical-containing albumin nanocomplex effectively delivers phytochemicals to immune cells that induce reactive oxygen species and inflammatory responses, thereby regulating the muscle loss signaling mechanism induced by reactive oxygen species and inflammatory responses, suppressing muscle cell atrophy, and promoting differentiation. This can improve muscle loss and prevent and treat muscle atrophy. Therefore, a composition containing the phytochemical-containing albumin nanocomplex of the present invention can be provided as a composition for improving muscle diseases.

Provided is a composition for preventing, improving, or treating muscular disorders including sulfonamide-based compounds or salts thereof. According to the present disclosure, the sulfonamide-based compounds or salts thereof may prevent inhibition of differentiation of myoblasts by regulating the expression of PHF20 and YY1. Accordingly, since the composition may prevent or alleviate muscle loss, promote muscle regeneration, and improve muscle exercise function, balance ability, and grip strength recovery ability through increased muscles and changes in ratio of muscle fibers, the composition may be effectively used for therapeutic agents, foods, or feeds for preventing, improving or treating muscle disorders, and improving muscle functions or muscle mass.

Provided herein is a method of ameliorating muscle loss in a subject induced from the treatment of the subject with a GLP-1 agonist with the administration to the subject of a therapeutically effective amount of a placenta derived biological material having a continuous lipid bilayer membrane

The invention relates to application of lactobacillus reuteri and / or metabolites thereof to preparation of a composition for retarding muscle loss, improving muscle endurance or retarding cell aging, wherein the lactobacillus reuteri is lactobacillus reuteri TCI979 with the preservation number of DSM34539.

Methods for treating diseases and disorders treatable by AMPK activation with cefin-1 and related compounds, such as metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, muscle loss, neuromuscular disorders, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular disease, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, eye diseases or disorders, ocular angiogenesis, β-hemochromocytic disorder, cancer, fibrosis, cancer cachexia, and mitochondrial diseases.

The present invention relates to a combination therapy of an approved GLP-1 receptor agonist treatment and a microorganism transformed with a cell surface display vector operably linked with a gene encoding myostatin and activin A proteins for the treatment of muscle loss related to obesity. The microorganism may be formulated to include pharmaceutically viable excipients, such as antiadherents, binders, carriers, coatings, colorants, disintegrants, diluents, flavorings, glidants, lubricants, preservatives, sorbents, or vehicles.

The application discloses application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating muscle loss, and the traditional Chinese medicine composition is prepared from raw medicinal materials in the following proportions by weight: Semen Euryae 150-350, Fructus Lycii 100-200, Schisandra chinensis 30-60, Cnidium 20-50, Chamaerops 20-50, Lepidium 20-50, Dipsacus 20-50, Cistanche 20-50, Rehmannia 30-60, Cyathula 20-50, Herba Epimedii 40-100, Rubus 20-50, Ginseng 15-35, Deer Horn 10-25, Sea Horse 15-35 and Melia 15-35. Animal experiments prove that the traditional Chinese medicine composition can improve the endurance and balance ability of a mouse with muscle loss, and can be used for preventing and treating muscle loss.

The present invention is directed to a method of treating muscle loss in a subject being treated for weight loss.

The present application relates to a peptide exhibiting muscle loss prevention and muscle mass promotion activities, and use thereof, and provides: a peptide consisting of an amino acid sequence of SEQ ID NO: 1; a pharmaceutical composition for preventing or treating a muscle disease, comprising the peptide as an active ingredient; and a food composition for preventing or ameliorating a muscle disease, comprising the peptide as an active ingredient.